呋塞米介入及增加核素活度对肝癌和肝硬化患者骨显像的改善

The influence of bone scintigraphy in hepatic carcinoma and hepatocirrhosis with furosemide interventional test and increase radioactivity

目的探讨肝癌、肝硬化患者核素骨显像的影响因素及如何提高显像质量。方法对90例肝癌、肝硬化患者行常规、呋塞米介入和增加核素活度三项核素骨显像，比较三者的显像结果。结果通过呋塞米介入，肝癌组骨／软组织（B／ST）摄取比值增加15％，有显著性差异（t=2．39，P〈0．05），肝硬化组和肝癌伴肝硬化组增加16％和20％（t=2．52，t=2．96，P〈0．01）。增加活度后各组B／ST分别增加26％、30％、31％（f=3．08，f=3．36，f=3．39，P〈0．01）。结论肝癌、肝硬化患者骨显像的影响因素主要是肾功能、腹水、化疗、贫血等，建议使用上述两种方法以提高显像质量。

Objective To investegat the influence factors of bone scintigraphy in hepatic carcinoma and hepatocirrhosis patients and how to improve image quality. Methods The routine bone scintigraphy, furosemide interventional test and increase radioactivity test were performed on 90 hepatic carcinoma and hepatocirrhosis. Results Bone-to-soft tissue ratio of hepatic carcinoma group was increased 15% after furosemide interventional test. There was significant difference （t= 2.39, P〈0.05）. Hepatocirrhosis without hepatic carcinoma and hepatic carcinoma followed hepatocirrhosis group were increased 16% and 20% （t= 2.52, t= 2.96, P〈0.01）. The B/ST ratio of three groups were increased 26%, 30%, 31% respectively after increase radioactivity test（ t =3.08, t =3.36, t =3.39, P〈0.01） . Conclusion Influence factors of bone scintigraphy in hepatic carcinoma and hepatocirrhosis are renal function, ascites, chemotherapy, anaemia et al. We suggest that use mentioned methods in order to improve image quality.